Archer Materials (ASX:AXE) partnered with UK-based electronics company Paragraf to develop the company's Biochip potassium ion sensor for testing chronic kidney disease, according to a Monday filing with the Australian bourse.
The agreement will be carried out in two stages, with each stage expected to take over three months at an estimated cost of AU$450,000, the filing said.
Shares were up 8% in midday trade Monday.